Stockreport

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 20...

IN8bio, Inc.  (INAB) 
PDF Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy ?d T cells (“DRI”) nearly doubling median progression-free survival (“mPFS”) to 13.0 months [Read more]